Adial Pharmaceuticals (ADIL) Expected to Announce Earnings on Tuesday

Adial Pharmaceuticals (NASDAQ:ADIL) is expected to announce its results before the market opens on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Adial Pharmaceuticals Price Performance

Shares of NASDAQ:ADIL opened at $2.33 on Tuesday. The company’s 50-day moving average price is $5.00 and its two-hundred day moving average price is $7.43. Adial Pharmaceuticals has a one year low of $2.30 and a one year high of $32.50. The stock has a market capitalization of $2.59 million, a PE ratio of -0.12 and a beta of 1.26.

Hedge Funds Weigh In On Adial Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADIL. Armistice Capital LLC acquired a new stake in shares of Adial Pharmaceuticals during the 4th quarter worth $562,000. Citadel Advisors LLC bought a new stake in Adial Pharmaceuticals during the third quarter worth about $51,000. Finally, Jane Street Group LLC grew its stake in Adial Pharmaceuticals by 887.3% during the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock worth $27,000 after buying an additional 109,500 shares in the last quarter. 16.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ADIL has been the subject of several analyst reports. UBS Group set a $8.00 target price on shares of Adial Pharmaceuticals in a research note on Wednesday, February 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Adial Pharmaceuticals in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Adial Pharmaceuticals currently has an average rating of “Hold” and an average price target of $22.75.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.